FDA approves first FOP treatment Regeneron's PASATRU

The FDA approved Regeneron's PASATRU (garetosmab-grts), the first therapeutic for fibrodysplasia ossificans progressiva, showing a 90%+ reduction in heterotopic ossification lesions.